Re: Transition to adulthood with a bladder augmentation: histopathologic concerns

Ines Mendes Pina 1, Ahmed M. Omar 1, Rauf N. Khadr 2, Michael S. Floyd Jr. 1, 2

1 Department of Reconstructive Urology, St Helens & Knowsley Hospital NHS Trust, Whiston Hospital, Liverpool, United Kingdom, UK; 2 Northwest Regional Spinal Cord Injury Unit, Southport & Ormskirk NHS Foundation Trust, Town Lane, Kew, Merseyside, United Kingdom, UK

To the editor,

We read with interest the recent paper by Mammadov et al. examining the concerns regarding histological changes in adult neurogenic patients who have undergone bladder augmentation with bowel interposition as an adolescent or in childhood (1).

The authors report a small study involving 20 patients who underwent selective anatomic bladder biopsies following augmentation for either neurogenic bladder, exstrophy or bladder neck trauma.

Two patients underwent open bladder biopsy as a simultaneous stone extraction procedure was planned. Neuropathic patients with a reconstructed or ablated urethra pose a challenge for the Urologist as they do not have dependant bladder drainage (2). Specific to the neurogenic patient with bladder calculi the authors should acknowledge that mitrofanoff cystolitholapaxy and concomitant bladder biopsy has been reported using a minimally invasive, hybrid technique thus avoiding the morbidity of open surgery (3).

Mammadov et al. reported no malignant histology in the study but did detect 2 cases of squamous metaplasia and 1 case of intestinal metaplasia (1). One case of squamous metaplasia had a history of bladder stones similar to the case reported by Floyd Jr et al. (3).

In 2011, Higuchi et al examined 250 surveillance cystoscopies and although 4 lesions were identified, none were malignant leading the authors to conclude that annual surveillance cystoscopy was not cost effective (4). A separate publication by Higuchi et al also commented on immunosuppression as an independent risk factor for neoplastic development in bladder augmentation patients (5) and this has not been addressed by Mammadov et al.

The authors conclude by stating that surveillance cystoscopy in augmented patients less than 5 years post operatively is now limited to those with symptoms. This is a very pertinent clinical point. Hamid et al. detected no malignancy in a series of 92 augmented and substituted patients undergoing surveillance cystoscopy but detected higher rates of chronic inflammation in the augmented group (6). Furthermore, they concluded by stating that surveillance cystoscopy was not merited in patients less than 15 years post operatively but advised that investigations should be prompted by development of appropriate symptoms in these patients (6).
REFERENCES


Correspondence address:
Ines Mendes Pina, MUDr
Saint Helen’s and Knowsley Teaching Hospitals NHS Trust - Urology
Whiston Hospital Warrington Road
Prescot L35 5DR
United Kingdom of Great Britain and Northern Ireland
E-mail: ines.pina@doctors.org.uk

Submitted for publication:
January 15, 2018

Accepted after revision:
January 22, 2018

Published as Ahead of Print:
March 19, 2018

ARTICLE INFO
Int Braz J Urol. 2018; 44:850-1